Almac Profits Up 30%
News May 28, 2014
Almac recorded pre-tax profits of £19.2m in 2013, up around 30% on the previous year, it has announced.
The company also saw turnover increase, up by 8% from £300m to £325m.
Around 3,400 people now work for Almac globally, with over 2,000 based at their Craigavon Headquarter site.
Almac provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors including all the world leaders and the company has seen significant growth in the past few years with staff retention rates remaining high.
The company has a major US operation in Pennsylvania and recently opened regional hubs in Singapore and Japan to help service increasing demand for its services in the Asian market.
Alan Armstrong, CEO of Almac, said: “Our long term objective is to be the leader in our chosen markets and following another successful year I’m pleased to report that we are showing sustained progress in reaching this goal.
“2013 was an exciting year for us with a major jobs boost in Craigavon as we completed a non-GMP drug development facility and expanded our manufacturing capabilities, announced a £13m investment in cancer research projects with Queen’s University and signed a $9m deal with Genomic Health securing the rights to further develop and commercialize our breast cancer test.
“We have continued to invest in research and development and capital programmes and this year is set to be another successful one both at our headquarters in Craigavon and globally, following the opening of our new offices in Asia, and looking ahead to the launch of our new facility in Singapore early next year.”
Almac will open a new clinical trial secondary packaging facility in Singapore at the start of next year to better enable just-in-time supply management and support drug pooling strategies, which further optimize the supply chain, minimize wastage and reduce costs.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018